Prednisolone Pharmaceuticals: Announcement on the marketing approval of voriconazole injections from the Norwegian Medicines Agency
Apr 17 06:12 ET
Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Finnish National Drug Administration
Apr 8 05:48 ET
Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Swedish Medicines Agency
Apr 7 12:00 ET
Puri Pharmaceuticals: Announcement on Daptomycin for injections obtained marketing approval from the German Federal Institute for Drugs and Medical Devices (BfArM)
Apr 3 06:20 ET
Puli Pharmaceuticals: Announcement on the change of signed accountant
Apr 3 06:18 ET
Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the first quarter of 2024
Apr 1 06:36 ET
Puri Pharmaceuticals: Notice on submission of 8- (2-hydroxybenzamide) sodium caprylate (SNAC) pharmaceutical excipients to the U.S. DMF
Mar 14 06:32 ET
Puri Pharmaceuticals: Announcement on obtaining marketing approval for injectable pantoprazole sodium from the Department of Pharmacy of the Ministry of Health of Israel
Mar 5 02:58 ET
Puri Pharmaceuticals: Announcement on obtaining marketing approval for sodium nitrate injections in Germany
Feb 6 06:27 ET
Puli Pharmaceuticals: Announcement on 2024 Interest Payments on Convertible Corporate Bonds
Feb 2 05:43 ET
Puli Pharmaceuticals: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Jan 26 04:52 ET
Puli Pharmaceuticals: Legal Opinion of the 2024 First Extraordinary General Meeting of Shareholders
Jan 26 04:51 ET
Puli Pharmaceuticals: Prompt Announcement on Convening the First Extraordinary General Meeting of Shareholders in 2024
Jan 22 04:20 ET
Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for injectable voriconazole in Canada
Jan 11 02:46 ET
Puli Pharmaceuticals: Announcement on the launch of foreign exchange hedging business by the company and its wholly-owned subsidiaries
Jan 10 11:00 ET
Puli Pharmaceuticals: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Jan 10 11:00 ET
Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the fourth quarter of 2023
Jan 2 04:10 ET
Puli Pharmaceuticals: Announcement on obtaining US drug clinical trial approval for PLAT001 for injection
Jan 1 18:52 ET
Pulley Pharmaceuticals: Announcement on the resignation of securities affairs representative
Dec 13, 2023 02:56 ET
Pulley Pharmaceuticals: Announcement on Pantoprazole Sodium for Injection Obtaining Marketing Approval from the Health Sciences Authority of Singapore
Dec 10, 2023 11:00 ET
No Data
No Data